Justin Briggs

Justin Briggs is a highly experienced scientific entrepreneur and investor, primarily focusing on deep technology and biotechnology. He has a strong track record of building and supporting companies at the intersection of biology, chemistry, and engineering, with over $80 million in investments led and $270 million in capital deployed across more than thirty companies. justinbriggs+1

He demonstrates significant operational expertise, having worked in nearly a dozen biotech, nanotech, robotics, and software companies. This hands-on experience, from bench research to clinical trials and commercialization, allows him to deeply understand and support scientific founders and their ventures. justinbriggs+2

Justin is actively involved in board leadership, currently serving on the boards of Iridia, LyGenesis, and Morphoceuticals. His previous board roles include Elevian, IVIVA Medical (acquired), Zafrens, Gilgamesh Pharmaceutical, and Dimension Inx, showcasing his commitment to guiding innovative companies. justinbriggs+3

He is a recognized drug developer with experience in bringing medicines from the laboratory bench through clinical trials across various disease areas and regulatory jurisdictions. His work at Tetherex Pharmaceuticals, Accele BioPharma, and Altheus Therapeutics highlights his expertise in novel therapeutics, biologics, and drug discovery. justinbriggs+1

Beyond his direct investment and operational roles, Justin is a founder of multiple ventures, including TomorrowScale (a podcast and venture firm), SnapLab Technologies (lab automation AI), and Chorus Labs (productivity software, acquired 2015), indicating a strong entrepreneurial drive. justinbriggs+1

Justin possesses a unique blend of scientific and business acumen, holding a degree in Biomedical Sciences and an MBA with high honors. He is also a co-inventor on multiple issued patents and an author of peer-reviewed publications, solidifying his deep technical and intellectual contributions. justinbriggs+3